As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Following a second day of stock market gains, investors looked forward to earnings reports from Eli Lilly and Amazon.

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Shares of Eli Lilly & Co. were headed for their worst day ... of growth for the quarter,” said Chief Executive David Ricks. Tomi Kilgore is MarketWatch's deputy investing and corporate news ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's largest healthcare company, with a market cap that topped $860 billion at one ...

Eli Lilly’s Omvoh (mirikizumab-mrkz) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderately to severely active Crohn’s disease. Crohn’s disease is one of the ...

Eli Lilly forecasts $45 billion in 2024 revenue ... During the conference, David Ricks outlined two reasons for the guidance update: The diabetes GLP market, in December, outperforms the rest ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Eli Lilly shares could remain under the microscope on Wednesday after falling sharply ...

Eli Lilly and Company (NYSE:LLY) shares slid 6.6% to $744.91, after it said it expects Q4 revenue at $13.5 billion- weaker than street expectations of $14.08 billion. The miss was driven largely ...